Results 231 to 240 of about 490,842 (303)

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

open access: yes
Transfusion, EarlyView.
Thane Kubik   +2 more
wiley   +1 more source

Alzheimer's disease and related dementias (ADRD) after COVID‐19 infection: trends and disparities

open access: yesAlzheimer's &Dementia: Behavior &Socioeconomics of Aging, Volume 2, Issue 2, June 2026.
Abstract INTRODUCTION Coronavirus disease 2019 (COVID‐19) may accelerate neurocognitive decline, but its association with incident mild cognitive impairment (MCI), Alzheimer's disease and related dementias (ADRD), and racial and ethnic disparities remains unclear.
Sumedha Gupta, Kosali Simon, Brea Perry
wiley   +1 more source

Hepatocyte growth factor/c‐Met signaling axis in human diseases: Mechanistic insights and therapeutic potential

open access: yesJournal of Cell Communication and Signaling, Volume 20, Issue 2, June 2026.
Figure 1 visually summarizes the core biological functions and therapeutic potential of the HGF/c‐Met signaling axis. Abstract Hepatocyte growth factor (HGF) is a multifunctional cytokine that activates the tyrosine kinase activity of its specific receptor, c‐Met (mesenchymal–epithelial transition factor).
Hongqin Sun   +7 more
wiley   +1 more source

DAMP Laden Extracellular Vesicles From the Airways of Patients With Severe SARS‐CoV‐2 Respiratory Infection Compromise Inflammation and Cellular Metabolism

open access: yesJournal of Extracellular Vesicles, Volume 15, Issue 6, June 2026.
Extracellular vesicles from severe COVID‐19 airways carry depleted miRNAs and elevated DAMPs, reprogramming monocytes toward senescence, impaired metabolism, and predominantly reduced cytokine responses. However, they drive excess IL‐8 production, amplifying neutrophil recruitment and dysfunctional inflammation across the respiratory tract.
April Rees   +14 more
wiley   +1 more source

Multi‐Layered Genomic and Clinical Analysis Identifies Novel Variants, Co‐Occurring Single Nucleotide Polymorphism Pairs, and Clinical Determinants of Host‐Pathogen Interaction in COVID‐19 Severity

open access: yesJournal of Medical Virology, Volume 98, Issue 6, June 2026.
ABSTRACT Host genetic factors may contribute to COVID‐19 severity. To identify genetic variants influencing COVID‐19 severity progression, whole‐exome sequencing was performed, followed by an exome‐wide association study on 191 hospitalized patients categorized into three severity groups.
Doris Repušić   +7 more
wiley   +1 more source

Persistent Arrhythmogenic Effects of COVID‐19: A Comprehensive Analysis of Device Implantation and Antiarrhythmic Interventions in Japan

open access: yesJournal of Arrhythmia, Volume 42, Issue 3, June 2026.
COVID‐19 was associated with a sustained increase in device implantation and arrhythmia‐related interventions over 2 years. In a nationwide propensity score‐matched cohort, risks of pacemaker, ICD, CRT implantation, ablation procedures, and antiarrhythmic medication initiation remained higher after COVID‐19, supporting long‐term cardiovascular ...
Daisuke Miyamori   +2 more
wiley   +1 more source

Organoids: From Bench to Bedside Applications

open access: yesMedComm, Volume 7, Issue 6, June 2026.
Organoids, as a groundbreaking biomedical research platform, utilize adult stem cells (ASCs), embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs) as sources. By integrating specific growth and differentiation signals within an extracellular matrix (e.g., Matrigel), organoids guide cells to self‐assemble into three‐dimensional ...
Kelin Li   +6 more
wiley   +1 more source

Acute Lung Injury: From Molecular Circuits to System‐Level Therapeutics

open access: yesMedComm, Volume 7, Issue 6, June 2026.
This visual summary illustrates the paradigm shift from linear pathways to network medicine in ALI. Three interconnected circuits—innate immunity, immunometabolism, and cell death (PANoptosis)—drive disease progression under multiorgan crosstalk (gut–lung, brain–lung).
Yaoli Hou   +10 more
wiley   +1 more source

Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study

open access: yesMuscle &Nerve, Volume 73, Issue 6, Page 1025-1031, June 2026.
ABSTRACT Introduction/Aims Current therapeutic management of juvenile myasthenia gravis (JMG) predominantly relies on conventional immunosuppressive therapies and expert consensus extrapolated from adult data, creating a critical gap in high‐quality, pediatric‐specific clinical evidence.
Jing Lin   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy